Patent Case Watch

Patent opinions from the Eastern District of Texas and the U.S. Court of Appeals for the Federal Circuit

E.D. Tex.

Allergan, Inc. v. Sandoz Inc, No. 2:09-cv-00097 (E.D. Tex. Apr. 27, 2011)

Claims Construed
Claim Construction
Court
U.S. District Court for the Eastern District of Texas, Marshall Division
Case No.
No. 2:09-cv-00097, Dkt. No. 151
Decided
April 27, 2011
Judge
See opinion
Document
Memorandum Opinion and Order
Docket Entry
MEMORANDUM OPINION and ORDER. The Court adopts the constructions set forth in this opinion for the disputed terms of the patents-in-suit. The parties are ordered that they may not refer, directly or indirectly, to each others claim construc…
Length
32 pages

From the Opinion

The passage below is extracted verbatim from the opening of the document. It has not been editorially summarized — consult the full opinion for the court's complete reasoning.

I. INTRODUCTION Plaintiff Allergan, Inc. (―Allergan‖) owns approved New Drug Application (―NDA‖) No. 21-398 for Combigan® (brimonidine tartrate/timolol maleate ophthalmic solution) 0.2%/0.5%. Combigan® was approved by the Food and Drug Administration (―FDA‖) for the treatment of glaucoma and ocular hy pertension in October of 2007. U.S. Patent Nos.

Download Opinion (PDF)

Source: govinfo.gov USCOURTS collection · retrieved July 23, 2026 · Report an error

Other documents in this case